E2F1 and neoplasm: In this review, we emphasize current evidence of lncRNA-E2F1 interaction in the context of malignancies and highlight the feasible preclinical therapeutic modalities for targeting lncRNAs or E2F1, aiming to facilitate the translation of molecular crosstalk into clinical application, which holds immense promises for tumor eradication and ameliorating prognosis (Figure 1).